MY126527A - Novel dihydropyrimidines - Google Patents

Novel dihydropyrimidines

Info

Publication number
MY126527A
MY126527A MYPI99001481A MYPI19991481A MY126527A MY 126527 A MY126527 A MY 126527A MY PI99001481 A MYPI99001481 A MY PI99001481A MY PI19991481 A MYPI19991481 A MY PI19991481A MY 126527 A MY126527 A MY 126527A
Authority
MY
Malaysia
Prior art keywords
dihydropyrimidines
novel
compounds
formulae
relates
Prior art date
Application number
MYPI99001481A
Other languages
English (en)
Inventor
Siegfried Goldmann Dr
Thomas Kramer Dr
Ulrich Niewohner Dr
Karl-Heinz Schlemmer Dr
Olaf Weber Dr
Jorn Stolting Dr
Stoltefub J0Xdcrgen
Arnold Paebens Dr
Erwin Graef Dr
Stefan Lottmann Dr
Karl Deres Dr
Original Assignee
Bayer Schering Pharma Aktiemgesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Aktiemgesellschaft filed Critical Bayer Schering Pharma Aktiemgesellschaft
Publication of MY126527A publication Critical patent/MY126527A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
MYPI99001481A 1998-04-18 1999-04-16 Novel dihydropyrimidines MY126527A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19817264A DE19817264A1 (de) 1998-04-18 1998-04-18 Neue Dihydropyrimidine

Publications (1)

Publication Number Publication Date
MY126527A true MY126527A (en) 2006-10-31

Family

ID=7864972

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI99001481A MY126527A (en) 1998-04-18 1999-04-16 Novel dihydropyrimidines

Country Status (36)

Country Link
US (3) US6696451B1 (enExample)
EP (1) EP1080086B1 (enExample)
JP (2) JP4590097B2 (enExample)
KR (1) KR100636771B1 (enExample)
CN (1) CN1159311C (enExample)
AR (1) AR018187A1 (enExample)
AT (1) ATE223401T1 (enExample)
AU (1) AU740318B2 (enExample)
BG (1) BG64649B1 (enExample)
BR (2) BRPI9917862B8 (enExample)
CA (1) CA2328780C (enExample)
CO (1) CO5021127A1 (enExample)
CU (1) CU23049A3 (enExample)
CZ (1) CZ293482B6 (enExample)
DE (2) DE19817264A1 (enExample)
DK (1) DK1080086T3 (enExample)
ES (1) ES2183548T3 (enExample)
GT (1) GT199900056A (enExample)
HU (1) HUP0102372A3 (enExample)
ID (1) ID27263A (enExample)
IL (2) IL138584A0 (enExample)
MY (1) MY126527A (enExample)
NO (2) NO321985B1 (enExample)
NZ (1) NZ507569A (enExample)
PE (1) PE20000427A1 (enExample)
PL (1) PL193898B1 (enExample)
PT (1) PT1080086E (enExample)
RU (1) RU2245881C9 (enExample)
SI (1) SI1080086T1 (enExample)
SK (1) SK286407B6 (enExample)
SV (1) SV1999000047A (enExample)
TR (1) TR200003011T2 (enExample)
TW (1) TW548274B (enExample)
UA (1) UA63998C2 (enExample)
WO (1) WO1999054326A1 (enExample)
ZA (1) ZA200005136B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058302A1 (de) * 1999-03-25 2000-10-05 Bayer Aktiengesellschaft Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b
AU5568400A (en) 1999-06-23 2001-01-09 Ajinomoto Co., Inc. Novel dihydropyrimidine derivatives
AU3009801A (en) * 1999-12-22 2001-07-03 Bayer Aktiengesellschaft Combinations of medicaments for treating viral diseases
DE10012823A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013125A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013126A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10125131A1 (de) 2001-05-23 2002-12-05 Bayer Ag Verfahren zur Spaltung des Methyl 4-(2-chlor-4-fluorphenyl)-2-(3,5-difluor-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrmidincarboxylat-Racemats
US20040092735A1 (en) * 2002-11-08 2004-05-13 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of cefuroxime sodium
CN101104604B (zh) 2006-07-10 2011-03-02 北京摩力克科技有限公司 光学纯二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
CN101104617B (zh) * 2006-07-10 2010-06-23 北京摩力克科技有限公司 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
RU2452733C2 (ru) * 2007-04-27 2012-06-10 Пэдью Фарма Л.П. Антагонисты trpv1 и их применение
KR101173892B1 (ko) 2007-06-18 2012-08-16 선샤인 레이크 파르마 컴퍼니 리미티드 브로모-페닐 치환된 티아졸릴 디하이드로피리미딘
US8445457B2 (en) 2007-07-12 2013-05-21 Novartis Ag Oral pharmaceutical solutions containing telbivudine
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MY182403A (en) 2012-08-24 2021-01-25 Sunshine Lake Pharma Co Ltd Dihydropyrimidine compounds and their application in pharmaceuticals
KR20150054795A (ko) 2012-09-10 2015-05-20 에프. 호프만-라 로슈 아게 B형 간염 바이러스 감염의 치료 및 예방을 위한 6-아미노산 헤테로아릴다이하이드로피리미딘
CN103664899B (zh) * 2012-09-11 2017-06-16 广东东阳光药业有限公司 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用
WO2014074906A1 (en) * 2012-11-09 2014-05-15 Indiana University Research And Technology Corporation Alternative uses for hbv assembly effectors
TW201609652A (zh) * 2013-11-12 2016-03-16 陶氏農業科學公司 用於氟化化合物之過程(三)
JP6524081B2 (ja) 2013-11-19 2019-06-05 サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. ジヒドロピリミジン化合物及び医薬におけるその適用
AU2014356984B2 (en) 2013-11-27 2018-01-04 Sunshine Lake Pharma Co., Ltd. Processes for preparing dihydropyrimidine derivatives and intermediates thereof
KR20160133563A (ko) 2014-03-28 2016-11-22 선샤인 레이크 파르마 컴퍼니 리미티드 다이하이드로피리미딘 화합물 및 이의 약제학적 용도
CN105153164B (zh) * 2014-05-30 2018-10-30 齐鲁制药有限公司 作为hbv抑制剂的二氢嘧啶并环衍生物
ES2687606T3 (es) * 2014-05-30 2018-10-26 Qilu Pharmaceutical Co., Ltd. Derivado de bucle de dihidropirimido como inhibidor de HBV
CN105859708B (zh) 2015-02-07 2020-01-21 广东东阳光药业有限公司 二氢嘧啶衍生物的盐及其在药物中的应用
JP2020525490A (ja) * 2017-06-27 2020-08-27 ヤンセン ファーマシューティカ エヌ.ベー. ヘテロアリールジヒドロピリミジン誘導体及びb型肝炎感染を治療する方法
US10759774B2 (en) 2017-09-28 2020-09-01 The Curators Of The University Of Missouri Inhibitors of hepatitis B virus targeting capsid assembly
MX2020004839A (es) 2017-11-02 2020-10-16 Aicuris Gmbh & Co Kg Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb).
AR115131A1 (es) 2017-11-02 2020-12-02 Aicuris Gmbh & Co Kg Altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb)
MA52586A (fr) * 2018-05-08 2021-03-17 Janssen Sciences Ireland Unlimited Co Dérivés de dihydropyrimidine et leurs utilisations dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
UY38439A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Novedosas urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
UY38434A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
AR116948A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
AR117188A1 (es) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
AR116947A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
EP3873913A1 (en) * 2018-11-02 2021-09-08 AiCuris GmbH & Co. KG Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv)
AU2019409191A1 (en) 2018-12-20 2021-05-27 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections
CN113767102A (zh) 2019-04-30 2021-12-07 艾库里斯有限及两合公司 具有抗乙型肝炎病毒(hbv)活性的新的苯基和吡啶基脲类化合物
WO2020221811A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel oxalyl piperazines active against the hepatitis b virus (hbv)
AU2020265392A1 (en) 2019-04-30 2021-12-23 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis B virus (HBV)
CN113767101A (zh) 2019-04-30 2021-12-07 艾库里斯有限及两合公司 具有抗乙型肝炎病毒(hbv)活性的新的吲哚-2-甲酰胺类化合物
WO2020255016A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130304C (enExample) * 1964-02-12
CH550189A (de) 1971-01-08 1974-06-14 Ciba Geigy Ag Verfahren zur herstellung von neuen dibenzo (b,f) thiepincarbonsaeuren.
CH569043A5 (enExample) 1973-01-23 1975-11-14 Ciba Geigy Ag
US4371537A (en) * 1981-08-13 1983-02-01 The Dow Chemical Company Sulfur-substituted phenoxypyridines having antiviral activity
DE3234684A1 (de) 1982-09-18 1984-03-22 Bayer Ag, 5090 Leverkusen Neue dihydropyrimidine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
JPS60185764A (ja) 1984-03-05 1985-09-21 Wako Pure Chem Ind Ltd ピリジン誘導体の新規な製造法
US4698340A (en) 1984-07-19 1987-10-06 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives, processes for preparation thereof and composition containing the same
US4727073A (en) 1984-10-01 1988-02-23 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives and composition of the same
GB8906168D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
BR9713027A (pt) 1996-11-12 2000-01-25 Novartis Ag Derivados de pirazol úteis como herbicidas
SE9702564D0 (sv) 1997-07-02 1997-07-02 Astra Ab New compounds

Also Published As

Publication number Publication date
NO20045259L (no) 2000-12-13
PL343481A1 (en) 2001-08-27
CN1159311C (zh) 2004-07-28
SV1999000047A (es) 2000-06-23
DK1080086T3 (da) 2002-12-23
KR20010042788A (ko) 2001-05-25
CA2328780A1 (en) 1999-10-28
AU3813399A (en) 1999-11-08
EP1080086A1 (de) 2001-03-07
EP1080086B1 (de) 2002-09-04
BRPI9917862B8 (pt) 2021-05-25
JP2010241837A (ja) 2010-10-28
UA63998C2 (uk) 2004-02-16
US6696451B1 (en) 2004-02-24
CN1305471A (zh) 2001-07-25
ZA200005136B (en) 2001-03-02
TR200003011T2 (tr) 2001-01-22
JP5237332B2 (ja) 2013-07-17
RU2245881C2 (ru) 2005-02-10
WO1999054326A1 (de) 1999-10-28
ID27263A (id) 2001-03-22
JP2002512243A (ja) 2002-04-23
NO321985B1 (no) 2006-07-31
PT1080086E (pt) 2002-12-31
PE20000427A1 (es) 2000-06-25
NO20005215D0 (no) 2000-10-17
BR9909730A (pt) 2000-12-19
NO20005215L (no) 2000-12-13
ES2183548T3 (es) 2003-03-16
RU2245881C9 (ru) 2006-02-10
AR018187A1 (es) 2001-10-31
CZ20003871A3 (cs) 2001-01-17
BRPI9917862A2 (enExample) 2010-12-07
NZ507569A (en) 2002-04-26
US20040167135A1 (en) 2004-08-26
BG104812A (en) 2001-06-29
KR100636771B1 (ko) 2006-10-23
US20070117812A1 (en) 2007-05-24
TW548274B (en) 2003-08-21
NO329020B1 (no) 2010-07-26
SI1080086T1 (en) 2003-02-28
CZ293482B6 (cs) 2004-05-12
BR9909730B1 (pt) 2012-09-04
SK286407B6 (sk) 2008-09-05
DE19817264A1 (de) 1999-10-21
SK15652000A3 (sk) 2001-04-09
AU740318B2 (en) 2001-11-01
PL193898B1 (pl) 2007-03-30
CO5021127A1 (es) 2001-03-27
GT199900056A (es) 2000-10-07
US7514565B2 (en) 2009-04-07
IL138584A0 (en) 2001-10-31
HUP0102372A3 (en) 2003-01-28
HK1039119A1 (en) 2002-04-12
BG64649B1 (bg) 2005-10-31
DE59902573D1 (en) 2002-10-10
ATE223401T1 (de) 2002-09-15
CU23049A3 (es) 2005-06-24
BRPI9917862B1 (pt) 2013-05-07
CA2328780C (en) 2008-09-23
WO1999054326A8 (de) 1999-12-29
JP4590097B2 (ja) 2010-12-01
HUP0102372A2 (hu) 2001-12-28
IL138584A (en) 2006-09-05

Similar Documents

Publication Publication Date Title
MY126527A (en) Novel dihydropyrimidines
MY136520A (en) Novel compounds
GB0111186D0 (en) Novel compounds
MY144616A (en) Substituted dihydroquinazolines
MY133392A (en) Novel substituted pyrazole derivatives
EP1633740A4 (en) CHEMICAL COMPOUNDS
PT1416935E (pt) Derivados de 4-amino-6-fenil-pirrolo[2,3-d]pirimidina
MY134880A (en) Thiazolyl amide derivatives
BG105783A (en) Triazole compounds with dopamine-d3-receptor affinity
DK1200418T3 (da) Nematodicide trifluorbutener
IL145213A0 (en) Polyurethane solutions containing allkoxysilane structural units
YU60900A (sh) Novi kristalni oblici antivirusnog benzimidazolskog jedinjenja
GB0011203D0 (en) Chemical compounds
GB0216001D0 (en) Process and composition
AU2003288869A1 (en) PYRAZOLO (3,4-d) PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF H.PYLORI INFECTION
UA49884C2 (uk) ПОХІДНІ <font face="Symbol">a</font>-ГІДРОКСИКАРБОНОВОЇ КИСЛОТИ ТА ЛІКАРСЬКИЙ ЗАСІБ НА ЇХ ОСНОВІ
IL159993A0 (en) Platinum complexes and their use in cancer treatment
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
HU9201799D0 (en) New 2-amino-5-ciano-1,4-dihydropiridine-derivatives, process for their use and their use as medicaments
PL359409A1 (en) Compounds useful for the preparation of medicaments with phosphodiesterase iv inhibitory activity
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber